Scientist Outreach
HRT & Cognition
Private research hub
Incorrect password
Scientist Outreach:
HRT & Cognition
What this is
These emails ask four leading researchers the same core question: has anyone studied whether bioidentical 17β-estradiol suppresses the brain's alternative (non-glucose) fuel pathways? The research exists for CEE (conjugated equine estrogens) in metabolically compromised brains, but the bioidentical formulation equivalent has not been studied. If the answer is "no, nobody has done this," that is itself a publishable research gap.
The backstory: the Zhou et al. 2021 meta-analysis (23 RCTs) showed HRT had a statistically significant negative effect on global cognition in women over 60. The mechanism paper most likely to explain this is Espeland et al. 2015 (Diabetes Care): women with pre-existing glucose impairment who received CEE + MPA showed accelerated cognitive decline, while metabolically healthy women showed no harm. The hypothesis is that estrogen suppresses the brain's compensatory ketogenic shift, which is benign when glucose transport is intact and harmful when it is already impaired. Nobody has tested whether bioidentical estradiol does the same thing.
Dr. Roberta Diaz Brinton
Director, Center for Innovation in Brain Science, University of Arizona, Neuroscience, estrogen neuroprotection, brain bioenergetics, APOE4
Contact
Lab contact: Call 520-626-4681, ask for Heather Liber (lab admin)
Contact form: robertabrinton.com/contact
No direct faculty email address confirmed. Lab phone + contact form are the best routes.
Why her: She published the preclinical work establishing that the aging female brain undergoes a compensatory metabolic shift toward ketone utilization when glucose transport declines. Her lab is the origin of the "adaptive ketogenic shift" mechanism this question builds on.
Draft Email
Dear Dr. Brinton,
My name is Annette Thompson. I write about women's health and longevity for a lay audience, and I've been working through your research on brain bioenergetics and the metabolic transition that occurs in the aging female brain.
Your work on the shift from glucose to ketone-body utilization in the estrogen-deprived brain has been clarifying for me in a way that almost no other research has been. It explains something I couldn't reconcile: why HRT appears neuroprotective in some populations and potentially harmful in others.
I want to ask you about a gap I may have identified, and I'd value your read on whether it's real or whether I'm missing something obvious.
The mechanism you described -- estrogen suppressing the adaptive ketogenic shift that the brain initiates when glucose transport declines -- has been studied primarily with conjugated equine estrogens (CEE), often in combination with MPA. The Espeland et al. 2015 Diabetes Care paper showed that glucose-impaired women on CEE + MPA showed accelerated cognitive decline, while metabolically healthy women did not. That fits the mechanism: if the brain has already shifted to ketones as a compensatory fuel, exogenous estrogen suppressing that shift would be harmful. In a metabolically healthy brain, no such suppression would matter.
What I haven't been able to find is whether bioidentical 17β-estradiol has been studied in this specific context. Does it suppress the same compensatory ketogenic pathways as CEE? Or does the formulation difference matter at the receptor or metabolic level in a way that would change the prediction?
If this has been studied and I've missed it, I would genuinely appreciate the reference. If it hasn't been studied, I would be grateful to understand whether you think that's a meaningful gap or whether there are theoretical reasons to expect the same mechanism applies to bioidentical estradiol.
I'm not a researcher -- I'm a writer trying to get this right for the women I write for. Any guidance you can offer, even a brief response, would mean a great deal.
With respect and gratitude for your work,
Annette Thompson
SmartStrongAlive
[email protected]
Dr. Mark Espeland
Professor of Biostatistics and Data Science, Wake Forest School of Medicine, WHIMS, WHICAP, cognitive outcomes in hormonal trials
Contact
No direct email confirmed. His faculty page at Wake Forest showed no email address.
Try the Wake Forest faculty directory at school.wakehealth.edu or the department contact form for Biostatistics and Data Science.
Why him: He is the corresponding author on the 2015 Diabetes Care paper that identified the glucose-impairment modifier effect -- the specific mechanism paper this question is built on. He designed the WHIMS trial. He will immediately understand the question.
Draft Email
Dear Dr. Espeland,
My name is Annette Thompson. I write about women's health and longevity, and I've been studying your 2015 paper in Diabetes Care on HRT, pre-existing glucose impairment, and cognitive outcomes in WHIMS.
The finding that glucose-impaired women on CEE + MPA showed accelerated cognitive decline -- while metabolically healthy women did not -- resolved something I had been trying to reconcile for months. Your mechanism framing (estrogen suppressing the compensatory ketogenic shift that the glucose-impaired brain has already initiated) is, as far as I can tell, the most coherent explanation for why HRT appears to harm cognition in some populations and spare it in others.
I have one question, and I'll be direct about it: has this been studied with bioidentical 17β-estradiol?
The trials you describe used CEE, often combined with MPA. The KEEPS-Cog trial used bioidentical estradiol in recently postmenopausal women and found no cognitive harm -- but KEEPS-Cog enrolled metabolically healthy women, so the modifier effect you identified wouldn't be expected to appear there.
What I can't find is a trial that uses bioidentical estradiol in metabolically impaired women -- or any mechanistic data on whether bioidentical estradiol suppresses the same compensatory brain energy pathways as CEE. Is there published work on this I've missed? And if not, do you know of any planned trials or any theoretical reasons to expect the same effect -- or not?
I understand this is outside the scope of what I can reasonably ask of a researcher's time. I'm not a clinician or a scientist -- I'm a writer trying to get this right. If you have even a paragraph of direction, I would be deeply grateful.
Thank you for your work on WHIMS. It matters more than the citation counts suggest.
Respectfully,
Annette Thompson
SmartStrongAlive
[email protected]
Dr. Pauline Maki
Professor of Psychiatry and Psychology, University of Illinois Chicago, Menopause, HRT, cognition, formulation differences, KEEPS-Cog
Contact
Confirmed: [email protected]
Direct faculty email confirmed from UIC faculty page.
Why her: She is one of the principal investigators on KEEPS-Cog (bioidentical estradiol, recently postmenopausal women, no cognitive harm found) and a leading expert on formulation differences in hormonal trials. She is positioned to say exactly whether the bioidentical-vs-CEE distinction matters mechanistically and whether anyone has tested the glucose-impairment modifier with bioidentical estradiol.
Draft Email
Dear Dr. Maki,
My name is Annette Thompson. I write SmartStrongAlive, a publication for women 45-65 on hormones, longevity, and health. I try to write at a level of scientific rigor that the lay menopause-content space rarely reaches, and your work -- particularly KEEPS-Cog -- has been essential to getting this right.
I'm writing with a specific question that I've been unable to resolve from the published literature alone.
The Espeland et al. 2015 Diabetes Care paper identified a potential modifier effect: women with pre-existing glucose impairment showed accelerated cognitive decline on CEE + MPA, while metabolically healthy women did not. The proposed mechanism -- estrogen suppressing the compensatory ketogenic shift the glucose-impaired brain has already initiated -- is compelling and fits the pattern of results across WHIMS and WHICAP.
KEEPS-Cog used bioidentical 17β-estradiol in recently postmenopausal women and found no cognitive harm. But as I understand it, KEEPS-Cog enrolled metabolically healthy women with a mean age of 52.6 -- which means the glucose-impairment modifier wouldn't be expected to appear there even if it exists for bioidentical estradiol.
My question: has the glucose-impairment modifier been studied specifically with bioidentical 17β-estradiol? Is there any mechanistic evidence that bioidentical estradiol suppresses (or doesn't suppress) the brain's compensatory ketogenic shift in the same way CEE appears to? And if this hasn't been studied, do you think it's a meaningful gap -- or are there theoretical reasons to expect the formulation distinction doesn't matter at the brain energy level?
I'm also curious whether you're aware of any trials currently designed to test this. I want to be honest with my readers about what we know, what we don't, and what the honest uncertainty is -- and right now I'm not sure whether to say "we don't know if bioidentical estradiol is safer for glucose-impaired women" or whether that's an unfair way to frame the current evidence.
Thank you for considering this. I'd be grateful for any direction you can offer.
With respect,
Annette Thompson
SmartStrongAlive
[email protected]
Dr. Lisa Mosconi
Associate Professor of Neuroscience, Weill Cornell Medicine, PET imaging, brain bioenergetics, APOE4, estrogen and Alzheimer's prevention
Contact
Lab contact: [email protected] (Women's Brain Initiative lab email)
Contact form: lisamosconi.com contact page
No direct personal email confirmed. Lab email is the primary route for research inquiries.
Why her: She has PET imaging data on brain glucose metabolism in peri- and postmenopausal women, including APOE4 carriers. She is the only researcher in this group with the actual imaging technology to see what is happening in glucose-impaired brains under hormonal conditions. And her chief scientific collaborator is Roberta Brinton, who established the ketogenic shift mechanism.
Draft Email
Dear Dr. Mosconi,
My name is Annette Thompson. I carry the APOE4 allele. My mother has Alzheimer's. I write about women's health and longevity, and your research has been the most clarifying work I've encountered in trying to understand what I should actually do about my own risk.
I have a specific scientific question, and I want to be direct about what I'm actually asking.
Your PET imaging work shows that APOE4-positive women begin experiencing brain glucose hypometabolism in perimenopause -- years before any clinical symptoms. Roberta Brinton's work on the adaptive ketogenic shift explains what I understand to be the mechanism: when glucose transport to neurons declines, the brain initiates a compensatory shift toward ketone-body utilization. That shift is protective while glucose impairment is modest; it may become insufficient as impairment progresses.
The Espeland et al. 2015 paper in Diabetes Care showed that women with pre-existing glucose impairment who received CEE + MPA showed accelerated cognitive decline, while metabolically healthy women did not. The proposed explanation: exogenous estrogen suppressed the compensatory ketogenic shift the already-impaired brain had initiated.
My question is narrow: has anyone used PET imaging to study what happens to brain energy metabolism specifically in glucose-hypometabolic women who are given bioidentical 17β-estradiol? Not CEE -- bioidentical estradiol. The distinction matters because most of the concerning trial data used CEE, often combined with MPA, and the formulations have different binding profiles.
I'm not asking you to speculate about treatment recommendations. I'm asking whether you're aware of any PET data on bioidentical estradiol in brains that already show glucose hypometabolism -- or whether, from your vantage point, that's a gap that exists in the literature. If it is a gap, I would like to name it accurately in what I write rather than leaving readers with a false impression that the bioidentical evidence is equivalent to the CEE evidence.
I recognize you must receive an enormous volume of email. Even a brief acknowledgment of whether this has or hasn't been studied would help me write about this accurately.
Thank you for your work. It is genuinely changing how women like me think about our futures.
With deep respect,
Annette Thompson
SmartStrongAlive
[email protected]